论文部分内容阅读
目的全面了解乳腺癌内源性耐药情况,实现肿瘤病人个体化化疗。方法应用荧光定量PCR方法检测51例术前未经化疗的乳腺癌和癌旁组织中mdr1、MRP、LRP、GST-π、TOPOⅡα、BCRP基因表达。结果这6个多药耐药基因在乳腺癌组织和癌旁组织中的阳性表达率均有显著统计学意义;mdr1、LRP、GST-π、TOPOⅡα在乳腺癌组织和癌旁组织之间的表达水平无显著统计学意义(P>0.05);MRP和BCRP在乳腺癌组织中的表达水平显著高于其在癌旁组织中的表达水平,差异有统计学意义(P<0.05)。结论 MRP和BCRP可能与乳腺癌的内源性耐药有关,mdr1、LRP、GST-π、TOPOⅡα的表达可能与乳腺癌的内源性耐药无关,乳腺癌患者进行术前的新辅助化疗是可行的。
Objective To comprehensively understand the endogenous drug resistance of breast cancer and achieve personalized chemotherapy for cancer patients. Methods The mRNA expressions of mdr1, MRP, LRP, GST-π, TOPOⅡα and BCRP in 51 cases of preoperative non-chemotherapy and adjacent tissues were detected by real-time fluorescence quantitative PCR. Results The positive rates of these six multidrug resistance genes in breast cancer tissues and paracancerous tissues were statistically significant. The expressions of mdr1, LRP, GST-π and TOPOⅡα between breast cancer tissues and adjacent tissues (P> 0.05). The expression levels of MRP and BCRP in breast cancer tissues were significantly higher than those in paracancerous tissues, the difference was statistically significant (P <0.05). Conclusions MRP and BCRP may be related to the endogenous resistance of breast cancer. The expression of mdr1, LRP, GST-π and TOPOⅡα may not be related to the endogenous resistance of breast cancer. The preoperative neoadjuvant chemotherapy for breast cancer patients is feasible.